Effect of 200 μg/day of vitamin k1 on the variability of anticoagulation control in patients on warfarin: A randomized controlled trial

Thrombosis Research

Volumn 132, Issue 3, 2013, Pages 329-335

  Majeed, Habeeb ^a   Rodger, Marc ^a   Forgie, Melissa ^a   Carrier, Marc ^a   Taljaard, Monica ^a   Scarvelis, Dimitrios ^a   Gonsalves, Carol ^a   Rodriguez, Rosendo A ^a   Wells, Philip S ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Anticoagulation; Double blind; Randomized; Thrombosis; vitamin K; Vitamin K antagonists

Indexed keywords

AMOXICILLIN; BENZODIAZEPINE DERIVATIVE; CEPHALOSPORIN; CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 4F2; DNA; LEVOTHYROXINE; MODAFINIL; NITROFURANTOIN; OXIDOREDUCTASE; PARACETAMOL; PHYTOMENADIONE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; STEROID 5ALPHA REDUCTASE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; WARFARIN;

ADULT; ALCOHOL CONSUMPTION; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICATION ERROR; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; VENOUS THROMBOEMBOLISM; VITAMIN SUPPLEMENTATION;

ANTICOAGULATION; DOUBLE-BLIND; RANDOMIZED; THROMBOSIS; VITAMIN K; VITAMIN K ANTAGONISTS;

ANTICOAGULANTS; DOUBLE-BLIND METHOD; DRUG SYNERGISM; FEMALE; GENOTYPE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PLACEBOS; POLYMORPHISM, GENETIC; THROMBOSIS; TREATMENT OUTCOME; VITAMIN K 1; WARFARIN;

EID: 84883810173     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2013.07.019     Document Type: Article

References (40)

1. J. Hirsh, V. Fuster, J. Ansell, and J.L. Halperin American Heart Association/American College of Cardiology Foundation guide to warfarin therapy J Am Coll Cardiol 41 2003 1633 1652
2. B. Furie, B.A. Bouchard, and B.C. Furie Vitamin K-dependent biosynthesis of gamma- carboxyglutamic acid Blood 93 1999 1798 1808
3. C. Van Walraven, A. Jennings, N. Oake, D. Fergusson, and A.J. Foster Effect of study setting on anticoagulation control: a systematic review and metaregression Chest 129 2006 1155 1166
4. N. Oake, D.A. Fergusson, A.J. Forster, and C. van Walraven Frequency of adverse events in patients with poor anticoagulation: a meta-analysis CMAJ 176 2007 1589 1594
5. E. Sconce, T. Khan, J. Mason, F. Noble, H. Wynne, and F. Kamali Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation Thromb Haemost 93 2005 872 875
6. A.M. Reese, L.E. Farnett, R.M. Lyons, B. Patel, L. Morgan, and H.I. Bussey Low-dose vitamin K to augment anticoagulation control Pharmacotherapy 25 2005 1746 1751
7. S.K. Ford, C.P. Misita, B.B. Shilliday, R.M. Malone, C.G. Moore, and S. Moll Prospective study of supplemental vitamin K therapy in patients on oral anticoagulants with unstable international normalized ratios J Thromb Thrombolysis 24 2007 23 27
8. W.A. Leong Cases in Anticoagulation Management Thromb Thrombolysis 25 2008 78 84
9. L. Earl, R. Pena, and J. Hutchinson Utilization of dietary vitamin K supplementation to aid in INR stabilization for patients on chronic anticoagulant therapy: a series of case reports J Thromb Thrombolysis 25 2008 91-91
10. E. Sconce, P. Avery, H. Wynne, and F. Kamali Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin Blood 109 2007 2419 2423
11. E.K. Rombouts, F.R. Rosendaal, and F.J. Van Der Meer Daily vitamin K supplementation improves anticoagulant stability J Thromb Haemost 5 2007 2043 2048
12. R. Couris, G. Tataronis, W. McCloskey, L. Oertel, G. Dallal, and J. Dwyer Dietary vitamin K variability affects International Normalized Ratio (INR) coagulation indices Int J Vitam Nutr Res 76 2006 65 74
13. T. Khan, H. Wynne, P. Wood, A. Torrance, C. Hankey, and P. Avery Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin Br J Haematol 124 2004 348 354
14. A. Holbrook, S. Schulman, D.M. Witt, P.O. Vandvik, J. Fish American College of Chest Physicians Evidence-based management of anticoagulant therapy: Antithrombotic therapy and prevention of Thrombosis. 9th ed: American College of Chest Physicians Evidence-based Clinical Practice Guidelines Chest 141 2 Suppl. 2012 e152S 1584S
15. R.M. Rospond, C.M. Quandt, G.M. Clark, and H.I. Bussey Evaluation of factors associated with stability of anticoagulation therapy Pharmacotherapy 9 1989 207 213
16. A. Copplestone, and S. Roath Assessment of therapeutic control of anticoagulation Acta Haematol 71 1984 376 380
17. V.K. Bhandari, F. Wang, A.B. Bindman, and D. Schillinger Quality of anticoagulation control: do race and language matter? J Health Care Poor Underserved 19 2008 41 55
18. J. Harenberg, C. Weiss, M. Felten, and L. Frölich Stability of the INR in relation to personality traits in patients on stable oral anticoagulant therapy ASH Annual meeting Blood 114 2009 4178
19. G.C. Flaker, J. Pogue, S. Yusuf, M.A. Pfeffer, S.Z. Goldhaber, and C.B. Granger Cognitive function and anticoagulation control in patients with atrial fibrillation Circ Cardiovasc Qual Outcomes 3 2010 277 283
20. A.D. Waterman, P.E. Milligan, L. Bayer, G.A. Banet, S.K. Gatchel, and B.F. Gage Effect of warfarin nonadherence on control of the International Normalized Ratio Am J Health Syst Pharm 61 2004 1258 1264
21. B.F. Gage, C. Eby, P.E. Milligan, G.A. Banet, J.R. Duncan, and H.L. McLeod Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin Thromb Haemost 91 2004 87 94
22. M.K. Higashi, D.L. Veenstra, L.M. Kondo, A.K. Wittkowsky, and S.L. Srinouanprachanh Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy JAMA 287 2002 1690 1698
23. M. Margaglione, D. Colaizzo, G. D'Andrea, V. Brancaccio, A. Ciampa, and E. Grandone Genetic modulation of oral anticoagulation with warfarin Thromb Haemost 84 2000 775 778
24. G. Dalloul, H. Ghanbari, R. Hasan, D. Feldman, R. Hourani, and D. Shkri The effect of vitamin K supplementation on anticoagulation stability in a community based cardiology practice Conference: 31st Annual Scientific Sessions of the Heart Rhythm Society Heart Rhythm 7(5 suppl. 1) 2010 S88
25. F.R. Rosendaal, S.C. Cannegieter, F.J. van der Meer, and E. Briët A method to determine the optimal intensity of oral anticoagulant therapy Thromb Haemost 69 1993 236 239
26. B.L. Svarstad, B.A. Chewning, B.L. Sleath, and C. Claesson The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence Patient Educ Couns 37 1999 113 124
27. A.L. Briggs, T.R. Jackson, S. Bruce, and N.L. Shapiro The development and performance validation of a tool to assess patient anticoagulation knowledge Res Social Adm Pharm 1 2005 40 59
28. S.M. Lavsa, A. Holzworth, and N.T. Ansani Selection of a validated scale for measuring medication adherence J Am Pharm Assoc 51 2011 90 94
29. B.A. Hutten, M.H. Prins, W.K. Redekop, J.G. Tijssen, S.H. Heisterkamp, and H.R. Büller Comparison of three methods to assess therapeutic quality control of treatment with vitamin K antagonists Thromb Haemost 82 1999 1260 1263
30. D.A. Fitzmaurice, P. Kesteven, K.M. Gee, E.T. Murray, and R. McManus A systematic review of outcome measures reported for the therapeutic effectiveness of oral anticoagulation J Clin Pathol 56 2003 48 51
31. G.P. Samsa, and D.B. Matchar Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management J Thromb Thrombolysis 9 2000 283 292
32. P.S. Wells, H. Majeed, S. Kassem, N. Langlois, B. Gin, and J. Clermont A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism Thromb Res 125 2010 e259 e264
33. P.S. Wells, A.M. Holbrook, N.R. Crowther, and J. Hirsh Interactions of warfarin with drugs and food Review. Ann Intern Med 121 1994 676 683
34. E.P. Gebuis, F.R. Rosendaal, E. van Meegen, and F.J. van der Meer Vitamin K1 supplementation to improve stability of anticoagulation therapy with vitamin K antagonists: a dose-finding study Haematologica 96 2010 583 589
35. S.E. Kimmel, Z. Chen, M. Price, C.S. Parker, J.P. Metlay, and J.D. Christie The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study Arch Intern Med 167 2007 229 235
36. N.J. Davis, H.H. Billett, H.W. Cohen, and J.H. Arnsten Impact of adherence, knowledge, and quality of life on anticoagulation control Ann Pharmacother 39 2005 632 636
37. E.A. Sconce, P.J. Avery, H.A. Wynne, and F. Kamali Vitamin K epoxide reductase complex subunit 1 (VKORC1) polymorphism influences the anticoagulation response subsequent to vitamin K intake: a pilot study J Thromb Haemost 6 2008 1226 1228
38. D. Tassies, C. Freire, J. Pijoan, S. Margall, J. Monteagudo, and A. Ordinas Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation Haematologica 87 2002 1185 1191
39. G. Palareti, C. Legnani, G. Guazzaloca, V. Lelia, B. Cosmi, and B. Lunghi Risks factors for highly unstable response to oral anticoagulation: a case-control study Br J Haematol 129 2005 72 78
40. P.S. Wells, A. Brown, Jaffey, L. McGahan, M.C. Poon, and K. Cimon Safety and effectiveness of point-of-care monitoring devices in patients on oral anticoagulant therapy: a meta-analysis Open Medicine 1 2007 E131 E146